Skip to main content

A Phase 3 Open-Label Clinical Study to Evaluate the Safety and Tolerability of Rebiotix RBX2660 (microbiota suspension) in Subjects with Recurrent Clostridium difficile Infection

Clinical Trial Grant
Duke Scholars

Administered By

Medicine, Gastroenterology

Awarded By

Rebiotix Inc.

Start Date

April 12, 2021

End Date

April 11, 2024
 

Administered By

Medicine, Gastroenterology

Awarded By

Rebiotix Inc.

Start Date

April 12, 2021

End Date

April 11, 2024